AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$TAK

Greenway Nicola Deidre Petal sold $235K of TAK

Greenway Nicola Deidre Petal (Chief Human Resources Officer) sold 12,980 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $18.11 ($0.24M total) on 2026-08-18.

Original reporting
SEC EDGAR · Greenway Nicola Deidre Petal
Published Aug 19, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
high confidence
Mentioned
$TAK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The disclosed sale is a routine insider transaction with minimal market relevance.

02

Market read

Limited relevance; small insider sale unlikely to affect stock price.

03

What to watch

Potential upcoming compensation or stock plan adjustments.

Relevance 4/10Novelty 4/10Timing: post-market 2026-08-18

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

$TAKNeutralHigh confidence
Context

Chief Human Resources Officer sold 12,980 shares for $235K, reducing her stake to 40,049 shares.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to market cap and insider holdings.

Market effects

Sector

None; Takeda operates in pharma sector with no broader effect.

Regional

No regional impact.

Global

Limited to Takeda investors.

Counterpoint

What could challenge this read

Sale could signal insider confidence if viewed as routine liquidity need.

Key entities

  • Person
    Greenway Nicola Deidre Petal

    Chief Human Resources Officer at Takeda Pharmaceutical.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min